

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BrainAurora Medical Technology Limited

脑动极光医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6681)

VOLUNTARY ANNOUNCEMENT

ENTERING INTO BRAIN HEALTH DIGITAL AI TECHNOLOGY SERVICE COOPERATION AGREEMENT WITH KIANG WU HOSPITAL IN MACAU

This announcement is made by BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司 (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purposes of keeping the shareholders and potential investors of the Company informed of the latest update on the business developments of the Group in the Hong Kong and Macau regions.

The board of directors (the “**Board**”) of the Company is pleased to announce that BrainAurora Medical Technology Digital Intelligence (Macau) Limited (腦動極光醫學科技數智(澳門)有限公司) (“**BrainAurora Macau**”), an indirect wholly-owned subsidiary of the Company, has recently officially entered into a Brain Health Digital AI Technology Service Cooperation Agreement (the “**Agreement**”) with Kiang Wu Hospital in Macau (“**Kiang Wu Hospital**”), pursuant to which both parties thereto will enter into a long-term strategic cooperation in the Macau region, focusing on the digital screening, assessment, training and full-process health management of cognitive impairment, and jointly develop a new full-chain brain health service model covering “hospital-community-home” (the “**Cooperation**”).

I. BACKGROUND OF THE COOPERATION

Macau is facing the dual challenges of a deeply aging population and a rising prevalence of cognitive impairment. The population aged 60 and above in Macau is approximately 120,000, which imposes sustained economic burden and social pressure on families, society, healthcare services and the nursing care system based on epidemiological data calculation.

Founded in 1871, Kiang Wu Hospital is the oldest and largest non-profit medical institution in Macau and is a key pillar for maintaining the balance and stability of the local healthcare system, integrating medical services, public health response, medical education and social stability functions. Through its massive volume of outpatient and inpatient services (consistently accounting for nearly 50% of inpatient services in Macau), it provides inclusive and accessible medical care under a non-profit model, serving as a reliable “family hospital” for many citizens for a long time. In addressing the challenges of deep population aging and the surge in cognitive impairment in Macau, Kiang Wu Hospital is not only a provider of cutting-edge medical care, but also a contributor to the community health system. The “Brain Health Program” initiated and promoted by the said hospital has established a complete

prevention and control network from community screening and early intervention to family support, serving as an important community defense line for Macau in dealing with dementia issues. At the same time, it carries on the core missions of clinical teaching, scientific research and the cultivation of local medical talents, thereby fundamentally assisting Macau in enhancing its independent medical capabilities.

The Group is the first leading digital therapeutics enterprise in the Chinese Mainland to combine brain science, clinical medicine, big data and artificial intelligence algorithms across fields, focusing on the full life-cycle management of cognitive impairment. The Cooperation marks the first large-scale clinical implementation of the Group's leading cognitive digital therapeutics solutions in the Macau Special Administrative Region, is a key step in expanding into the Guangdong-Hong Kong-Macau Greater Bay Area market and serving the national "Healthy China 2030" strategy, and also marks an important milestone step towards the international market.

II. MAIN CONTENT OF THE COOPERATION

Pursuant to the Agreement, the Cooperation will focus on the following core contents:

1. Co-establishment of a "Brain Health Center" and service system: both parties thereto will establish and operate a "Brain Health Center" within Kiang Wu Hospital based on the Group's "66Brain Science Brain Health Cloud Service" (六六腦科學健腦雲服務) platform. The center will provide one-stop services from early screening and precise assessment to digital cognitive training and disease course follow-up, establishing a full-cycle management model of "early screening – precise diagnosis – multidisciplinary intervention – community and home extension" within Kiang Wu Hospital.
2. Diagnosis and treatment services covering all age groups: the service targets include the population aged 60 and above at risk of and suffering from cognitive impairment, as well as pediatric patients aged 3 to 18 with neurodevelopmental disorders. Digital therapeutics treatment services can be provided in hospital or at home according to doctors' prescriptions.
3. Ensuring data security and compliance: all data generated from the services will be in strict compliance with relevant laws and regulations of Macau, with server deployed and data stored locally in Macau to achieve complete data localization without cross-border transmission, ensuring information security and compliance.
4. Joint scientific research and academic exchange: both parties thereto will integrate expert resources from the Chinese Mainland and Macau to jointly promote the construction of a brain health medical center and carry out relevant clinical research and cooperation to enhance regional academic influence.

III. REASONS FOR AND BENEFITS OF THE COOPERATION

The Board believes that the Cooperation is of the following strategic significance to the Group:

1. Establishing a benchmark and exploring the Greater Bay Area market: by establishing cooperation with the most influential private hospital in Macau, the Group has successfully created its first benchmark project for digital therapeutics in the Hong Kong and Macau regions, providing a replicable demonstration model for subsequent expansion in other cities within the Guangdong-Hong Kong-Macau Greater Bay Area.
2. Accumulating high-quality real-world data and carrying out further scientific research on cognitive functional diseases: by providing systematic brain health services to Macau residents, the Group will, together with Kiang Wu Hospital, accumulate valuable clinical and application data. These data assets comply with international standards, will feed back into the algorithm optimization and product iteration of cognitive functional disease diagnosis and treatment services in Macau, further carry out scientific research on disease diagnosis and treatment together with Kiang Wu Hospital, consolidate the technological leading advantages in providing cognitive diagnosis and treatment services for local residents, and provide better diagnosis and treatment services for Macau residents.
3. Creating social and economic benefits: the Cooperation directly responds to the urgent community health needs in Macau and is expected to reduce the incidence of severe dementia through early intervention, thereby alleviating the overall disease burden of society. At the same time, the Cooperation will also bring sustainable service income to the Group and explore new growth points.
4. Strengthening the industry-university-research alliance network: the Cooperation further enriches the ecosystem alliance jointly built by the Group and authoritative medical institutions, forming synergy with the national-level project cooperation recently reached between the Company and the National Research Center for Rehabilitation Technical Aids of the Ministry of Civil Affairs, jointly promoting the standardized and large-scale application of cognitive digital therapeutics.

IMPLICATIONS UNDER THE LISTING RULES

To the best of the knowledge and belief of the Company, Kiang Wu Hospital in Macau and its ultimate beneficial owners are independent of and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)). The transactions contemplated under the Cooperation do not constitute any connected transaction of the Company under Chapter 14A of the Listing Rules, nor do they constitute any notifiable transaction of the Company under Chapter 14 of the Listing Rules.

The Cooperation has entered the initial execution stage and is expected to have a positive impact on the business development of the Group in the Guangdong-Hong Kong-Macau Greater Bay Area.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
Mr. Tan Zheng
Chairman and Executive Director

Hong Kong, February 8, 2026

As of the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive director; (ii) Mr. Li Sirui, Ms. Li Mingqiu and Mr. Deng Feng as non-executive directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive directors.